Kyverna Therapeutics, Inc. Finance Lease, Right-of-Use Asset, Amortization
Kyverna Therapeutics, Inc. (KYTX) reported Finance Lease, Right-of-Use Asset, Amortization of $41.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-11
- Kyverna Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $41.00K, a 82.70% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $107.00K, a 54.85% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $102.00K, a 56.96% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $154.00K, a 35.02% decline year-over-year.
- Kyverna Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2025 was $730.00K, a 23.08% decline from fiscal 2024.
- Kyverna Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2024 was $949.00K, a 13.25% increase from fiscal 2023.
- Kyverna Therapeutics, Inc. finance lease, right-of-use asset, amortization for fiscal 2023 was $838.00K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.00K 10-Q · filed 2026-08-11 | $193.00K 10-Q · filed 2026-08-11 | $250.00K derived: sum of 3 quarters · filed 2026-08-11 | $404.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $107.00K 10-Q · filed 2026-05-12 | $209.00K derived: sum of 2 quarters · filed 2026-05-12 | $363.00K derived: sum of 3 quarters · filed 2026-05-12 | $600.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $256.00K derived: sum of 2 quarters · filed 2026-03-26 | $493.00K derived: sum of 3 quarters · filed 2026-08-11 | $730.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $154.00K 10-Q · filed 2025-11-12 | $391.00K derived: sum of 2 quarters · filed 2026-08-11 | $628.00K 10-Q · filed 2025-11-12 | $865.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $237.00K 10-Q · filed 2026-08-11 | $475.00K 10-Q · filed 2026-08-11 | $711.00K derived: sum of 3 quarters · filed 2026-08-11 | $948.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $237.00K 10-Q · filed 2026-05-12 | $474.00K derived: sum of 2 quarters · filed 2026-05-12 | $711.00K derived: sum of 3 quarters · filed 2026-05-12 | $948.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $237.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $474.00K derived: sum of 2 quarters · filed 2026-03-26 | $711.00K derived: sum of 3 quarters · filed 2026-03-26 | $949.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $237.00K 10-Q · filed 2025-11-12 | $474.00K derived: sum of 2 quarters · filed 2025-11-12 | $712.00K 10-Q · filed 2025-11-12 | $942.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $237.00K 10-Q · filed 2025-08-12 | $475.00K 10-Q · filed 2025-08-12 | $705.00K derived: sum of 3 quarters · filed 2025-08-12 | $921.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $237.00K 10-Q · filed 2024-05-14 | $468.00K derived: sum of 2 quarters · filed 2025-03-27 | $684.00K derived: sum of 3 quarters · filed 2025-03-27 | $885.00K derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-12-31 | $231.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $447.00K derived: sum of 2 quarters · filed 2025-03-27 | $648.00K derived: sum of 3 quarters · filed 2025-03-27 | $838.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $216.00K 10-Q · filed 2024-11-13 | $417.00K derived: sum of 2 quarters · filed 2024-11-13 | $607.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $201.00K 10-Q · filed 2024-08-12 | $386.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $185.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |